Free shipping on all orders over $ 500

PF-06700841

Cat. No. M10437

All AbMole products are for research use only, cannot be used for human consumption.

PF-06700841 Structure
Synonym:

Brepocitinib

Size Price Availability Quantity
5mg USD 70  USD70 In stock
10mg USD 120  USD120 In stock
25mg USD 278  USD278 In stock
50mg USD 500  USD500 In stock
100mg USD 830  USD830 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

PF-06700841 is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. PF-06700841 also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively. PF-06700841 has good potency against IL6/pStat1 in the CD3+ cellular subset (IC50 of 81 nM), but lower inhibition of IL6/pSTAT3, again in the CD3+ cellular subset (IC50 of 641 nM). PF-06700841 also inhibits the JAK1/JAK3 driven γ-common chain cytokines, represented by IL-15/pStat5 and IL-21/pSTAT3 with reasonable potency (HWB IC50s of 238 and 204 nM, respectively). PF-06700841 inhibits EPO/pSTAT5 (JAK2 homodimer) in HWB spiked with CD34+ progenitor cells (IC50 of 577 nM). IL10/pSTAT3 (TYK2/JAK1) and IL27/pSTAT3 (JAK1/JAK2/TYK2) are also inhibited by PF-06700841 with IC50s of 305 nM and 86 nM, respectively.

In vivo, PF-06700841 (3-30 mg/kg; oral administration; for 7 consecutive days; female Lewis rats) treatment significantly reduces paw volume increase in a dose-dependent manner.

Chemical Information
Molecular Weight 389.40
Formula C18H21F2N7O
CAS Number 1883299-62-4
Solubility (25°C) DMSO 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] James G Krueger, et al. J Am Acad Dermatol. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis

[2] Christine E Jo, et al. Int J Dermatol. TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors

[3] Seth B Forman, et al. J Invest Dermatol. TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial

[4] Fathima Ferial Ismail, et al. Expert Rev Clin Pharmacol. JAK inhibition in the treatment of alopecia areata - a promising new dawn?

[5] Ana M Montilla, et al. Dermatol Ther (Heidelb). Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata

Related JAK Products
iJak-381 

iJak-381 is a JAK1/2 inhibitor with anti-inflammatory activity.

Ritlecitinib (malonate)

Ritlecitinib (PF-06651600) malonate is an orally active and selective JAK3 inhibitor with an IC50 of 33.1 nM.

Deuruxolitinib

Deuruxolitinib is a deuterated Ruxolitinib (INCB18424), which modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research of hair loss disorders.

A-005

A-005 is a potentially first-in-class, brain-penetrating TYK2 allosteric inhibitor for studies related to neuroinflammatory and neurodegenerative diseases.

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

  Catalog
Abmole Inhibitor Catalog




Keywords: PF-06700841, Brepocitinib supplier, JAK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.